term
uveiti
compris
group
intraocular
inflammatori
condit
directli
indirectli
affect
iri
ciliari
bodi
choroid
collect
known
uveal
tract
well
retina
optic
nerv
vitreou
case
etiolog
uveiti
unknown
howev
associ
autoimmun
diseas
infect
viral
fungal
parasit
trauma
uveiti
result
signific
visual
impair
thought
account
case
total
blind
unit
state
us
develop
world
posterior
uveiti
account
estim
peopl
us
uveiti
sever
form
diseas
primari
caus
vision
loss
patient
uveiti
cystoid
macular
edema
cme
andor
cataract
cme
lead
caus
vision
loss
posterior
uveiti
treatment
aim
reduc
cme
therefor
effect
treatment
uveiti
corticosteroid
consid
mainstay
noninfecti
uveiti
treatment
howev
sinc
diseas
typic
chronic
natur
patient
often
requir
longterm
repeat
treatment
either
topic
system
corticosteroid
sever
case
uveiti
multipl
round
subtenon
intravitr
corticosteroid
inject
well
system
corticosteroid
may
necessari
potenti
complic
endophthalm
vitreou
hemorrhag
retin
detach
follow
use
repeat
intravitr
inject
substanti
system
corticosteroid
requir
high
dosag
achiev
therapeut
concentr
eye
associ
system
side
effect
includ
hypertens
hyperglycemia
increas
suscept
infect
immunosuppress
agent
effect
treatment
option
associ
seriou
potenti
lifethreaten
system
advers
event
ae
renal
hepat
failur
bone
marrow
suppress
thu
therapi
usual
reserv
patient
sever
uveiti
unrespons
corticosteroid
therapi
corticosteroidinduc
complic
fluocinolon
acetonid
fa
intravitr
implant
mg
bausch
lomb
rochest
ny
usa
develop
provid
sustain
releas
corticosteroid
directli
vitreou
caviti
prolong
period
time
thu
avoid
complic
system
therapi
well
associ
repeat
corticosteroid
inject
approv
us
food
drug
administr
treatment
chronic
noninfecti
posterior
uveiti
nipu
fa
implant
insert
posterior
segment
small
par
plana
incis
sutur
sclera
implant
releas
fa
nomin
initi
rate
decreas
first
month
steadi
state
approxim
year
sustain
releas
fa
previous
report
result
longterm
continu
control
inflamm
implant
therefor
consid
particularli
suitabl
patient
chronic
inflamm
due
nipu
fa
intravitr
implant
evalu
three
larg
multicent
clinic
trial
cours
develop
thirtyfourweek
result
first
trial
result
second
trial
publish
previous
trial
conduct
predominantli
nonasian
patient
herein
report
result
third
trial
evalu
safeti
efficaci
implant
market
formul
fa
implant
predominantli
asian
popul
chronic
recurr
unilater
bilater
nipu
multicent
random
doublemask
dosecontrol
safeti
efficaci
studi
two
fa
intravitr
contain
mg
patient
chronic
recurr
unilater
bilater
nipu
clinicaltrialsgov
identifi
patient
inclus
exclus
criteria
present
tabl
studi
conduct
site
follow
countri
india
canada
australia
us
hong
kong
philippin
studi
receiv
institut
review
board
approv
center
studi
entri
provid
written
inform
consent
patient
receiv
full
explan
studi
procedur
independ
data
safeti
monitor
board
assess
safeti
efficaci
data
studi
progress
alert
sponsor
issu
aros
procedur
follow
accord
ethic
standard
respons
committe
human
experiment
institut
nation
helsinki
declar
revis
patient
random
via
computergener
random
procedur
receiv
one
two
fa
implant
dose
mg
studi
eye
patient
stratifi
accord
investig
site
method
nipu
manag
histori
system
corticosteroid
immunosuppress
agent
periocular
inject
corticosteroid
treatment
group
assign
patient
unilater
diseas
receiv
implant
affect
eye
patient
bilater
diseas
sever
affect
eye
underw
implant
criteria
determin
eye
sever
affect
includ
increas
number
recurr
nipu
preimplant
period
eye
similar
recurr
increas
therapi
preimplant
period
eye
similar
therapi
greater
degre
visual
acuiti
impair
eye
similar
visual
acuiti
judgment
physician
implant
eye
design
studi
eye
nonimpl
eye
design
fellow
eye
patient
bilater
diseas
consid
inclus
studi
investig
felt
would
possibl
control
fellowey
ocular
inflamm
local
therapi
fa
implant
surgic
implant
procedur
describ
detail
elsewher
briefli
polymerbas
intravitr
implant
contain
sustainedreleas
formul
fa
tablet
mm
thick
encas
silicon
elastom
cup
attach
heatcur
polyvinyl
alcohol
sutur
tab
implant
releas
fa
approxim
wherea
implant
releas
fa
rate
approxim
initi
decreas
approxim
period
surgic
implant
perform
local
gener
anesthesia
placement
implant
inferonas
inferotempor
quadrant
posterior
segment
par
plana
par
plana
infus
line
place
reduc
possibl
globe
collaps
vitrectom
eye
ethicon
inc
somervil
nj
usa
sutur
anchor
implant
top
surfac
implant
face
front
eye
one
week
postimplant
patient
discontinu
use
exist
therapi
ocular
inflamm
follow
receiv
oral
corticosteroid
reduc
use
least
week
approxim
per
week
dose
reach
mgday
week
complet
discontinu
system
treatment
receiv
topic
corticosteroid
gradual
taper
dosag
hourli
use
onceperday
use
week
complet
discontinu
system
treatment
receiv
immunosuppress
therapi
gradual
taper
dosag
period
investig
discret
patient
evalu
day
week
visit
followup
evalu
visit
conduct
interv
addit
year
evalu
also
describ
previous
includ
bestcorrect
visual
acuiti
bcva
applan
tonometri
slitlamp
biomicroscopi
indirect
ophthalmoscopi
autom
visual
field
test
humphrey
hematolog
serum
chemistri
test
optic
coher
tomographi
wide
avail
time
studi
conduct
consequ
patient
evalu
fluorescein
angiographi
screen
week
week
year
use
standard
protocol
macular
hyperfluoresc
evalu
mask
reader
describ
previous
three
type
comparison
util
studi
comparison
postimplant
find
retrospect
find
record
preimplant
period
dose
comparison
term
efficaci
safeti
withinpati
comparison
implant
eye
nonimpl
fellow
eye
patient
bilater
diseas
primari
efficaci
outcom
chang
uveiti
recurr
rate
implant
eye
period
preimplant
versu
year
postimplant
base
medic
chart
review
investig
record
whether
episod
preimplant
period
met
protocol
definit
postimplant
recurr
preimplant
recurr
maximum
anterior
chamber
ac
cell
score
maximum
vitreou
haze
score
maximum
reduct
visual
acuiti
logarithm
minimum
angl
resolut
logmar
snellen
equival
consid
suffici
sever
count
analysi
medic
chart
lack
suffici
detail
determin
whether
preimplant
recurr
met
protocol
definit
preimplant
recurr
record
analysi
recurr
within
postimplant
period
defin
follow
increas
compar
baselin
number
ac
cell
attribut
condit
nipu
increas
compar
baselin
vitreou
haze
attribut
condit
nipu
deterior
bcva
baselin
least
logmar
attribut
condit
nipu
recurr
consid
observ
seen
record
studi
investig
wherea
consid
imput
subject
seen
within
week
final
schedul
visit
secondari
efficaci
outcom
evalu
use
fellow
nonimpl
eye
control
studi
eye
includ
rate
time
postimplant
recurr
uveiti
chang
bcva
area
cme
use
fluorescein
angiogram
proport
eye
requir
system
therapi
periocular
inject
control
inflamm
use
preimplant
comparison
group
data
secondari
efficaci
outcom
includ
observ
imput
recurr
data
applic
safeti
outcom
includ
intraocular
pressur
iop
len
opac
estim
use
len
opac
classif
system
loc
ii
visual
field
ocular
nonocular
ae
visual
acuiti
ophthalmoscop
examin
find
ocular
ae
defin
unexpect
ocular
condit
consid
investig
clinic
signific
includ
limit
iop
increas
requir
medic
increas
dosagefrequ
iop
mm
hg
month
postsurgeri
iop
mm
hg
loss
line
visual
acuiti
baselin
last
schedul
visit
retin
tear
statist
analys
perform
use
sa
version
sa
institut
cari
nc
usa
mcnemar
test
correl
proport
use
analyz
primari
secondari
efficaci
end
point
time
uveiti
recurr
determin
via
analysi
test
use
betweendos
comparison
frequenc
uveiti
recurr
postimplant
statist
analys
safeti
variabl
perform
use
test
observ
stratifi
accord
investig
site
therapi
use
preimplant
period
distribut
time
first
iop
elev
mm
hg
analyz
via
proport
hazard
regress
observ
also
stratifi
accord
investig
site
therapi
use
preimplant
period
advers
event
compar
use
fisher
exact
test
descript
statist
calcul
analys
perform
intenttotreat
popul
defin
enrol
patient
receiv
implant
attend
least
one
postimplant
visit
uveiti
recurr
rate
implant
eye
shown
tabl
recurr
rate
eye
treat
implant
decreas
significantli
preimplant
period
postimplant
period
p
recurr
rate
eye
treat
implant
significantli
decreas
preimplant
rate
year
postimplant
period
postimplant
period
consist
vitro
drug
releas
data
indic
implant
deplet
fa
earlier
implant
contrast
uveiti
recurr
rate
nonimpl
fellow
eye
dose
group
combin
increas
eye
preimplant
period
postimplant
period
respect
p
versu
preimplant
period
fellow
eye
recurr
rate
fa
implant
group
similar
result
analysi
differ
pre
postimplant
recurr
rate
implant
studi
eye
nonimpl
fellow
eye
year
includ
imput
data
consist
base
observ
recurr
rate
except
imput
postimplant
recurr
rate
implant
studi
eye
combin
dose
group
significantli
lower
preimplant
recurr
rate
withinsubject
comparison
uveiti
recurr
rate
imput
followup
period
implant
eye
vs
nonimpl
eye
show
recurr
rate
significantli
lower
implant
eye
compar
nonimpl
eye
dose
group
combin
dose
group
p
analysi
use
evalu
time
recurr
uveiti
implant
nonimpl
eye
fig
differ
time
recurr
uveiti
implant
versu
nonimpl
eye
statist
signific
dose
group
p
recurr
fellow
nonimpl
eye
occur
much
earlier
recurr
implant
eye
fa
implant
group
uveiti
recurr
nonimpl
fellow
eye
increas
rapidli
first
day
implant
contralater
eye
wherea
implant
eye
signific
increas
uveiti
recurr
seen
approxim
day
implant
p
similar
result
observ
implant
group
although
trend
toward
recurr
uveiti
group
observ
begin
approxim
month
analysi
freedom
recurr
uveiti
compar
implant
eye
group
show
differ
dose
signific
hazard
ratio
ci
p
recurr
began
earlier
studi
eye
fa
implant
group
approxim
month
compar
fa
implant
dose
result
unexpect
base
known
vitro
drug
releas
data
analysi
implant
studi
eye
versu
nonimpl
fellow
eye
perform
patient
bilater
diseas
yield
similar
result
time
recurr
uveiti
significantli
longer
implant
eye
fellow
nonimpl
eye
p
data
shown
fa
intravitr
implant
reduc
need
adjunct
uveiti
treatment
proport
patient
requir
adjunct
treatment
control
inflamm
fa
implant
shown
tabl
proport
patient
requir
adjunct
system
therapi
decreas
approxim
postimplant
compar
preimplant
period
regardless
fa
implant
dosag
proport
eye
requir
adjunct
periocular
inject
topic
steroid
reduc
approxim
eye
receiv
fa
implant
respect
eye
receiv
fa
implant
implant
period
compar
preimplant
period
contrast
proport
nonimpl
fellow
eye
requir
periocular
inject
topic
steroid
postimplant
period
increas
remain
similar
preimplant
period
mean
chang
bcva
baselin
year
postimplant
implant
group
present
fig
mean
chang
baselin
logmar
bcva
year
year
postimplant
implant
eye
group
signific
p
group
group
combin
dose
group
visit
implant
eye
respect
improv
line
baselin
compar
nonimpl
eye
p
differ
dose
group
contrast
signific
differ
implant
eye
dose
fellow
nonimpl
eye
proport
eye
lost
line
bcva
baselin
visit
fig
instanc
line
loss
bcva
implant
eye
occur
immedi
postop
period
loss
line
bcva
also
often
observ
month
postimplant
cataract
preval
followup
visit
implant
eye
fa
implant
group
loss
line
bcva
compar
implant
eye
implant
group
mean
area
cme
measur
fluorescein
angiogram
decreas
screen
postimplant
visit
eye
receiv
implant
remaind
postimplant
followup
period
fa
implant
group
mean
area
cme
implant
eye
continu
decreas
mean
cme
area
use
last
observ
carri
forward
locf
eye
receiv
implant
experienc
reduct
area
cme
screen
postimplant
visit
howev
increas
visit
locf
mean
cme
nonimpl
fellow
eye
dose
group
combin
mean
area
cme
fluctuat
within
narrow
rang
postimplant
followup
period
area
cme
screen
similar
visit
approxim
number
patient
experienc
reduct
area
cme
baselin
postimplant
present
tabl
mean
exposur
fa
day
implant
group
day
implant
group
treatmentemerg
ocular
ae
includ
periop
event
report
implant
studi
eye
fellow
nonimpl
eye
tabl
present
frequent
occur
ae
implant
studi
eye
nonimpl
fellow
eye
implant
dose
group
combin
among
frequent
observ
ocular
ae
report
implant
studi
eye
elev
iop
cataract
commonli
associ
ocular
steroid
use
frequent
report
ae
implant
eye
eg
eye
pain
hypotoni
conjunctiv
hemorrhag
hyperemia
appear
primarili
associ
surgeri
fellow
eye
frequent
observ
ocular
ae
decreas
visual
acuiti
cataract
format
eye
pain
part
due
uveit
inflamm
experienc
effect
periocular
corticosteroid
inject
therapeut
level
fa
implant
explant
eye
n
implant
n
implant
cours
postimplant
period
seven
implant
remov
first
postimplant
year
eight
second
postimplant
year
four
third
postimplant
year
two
common
reason
attribut
explant
elev
iop
despit
maxim
medic
therapi
n
implant
n
implant
hypotoni
associ
implant
wound
site
leak
n
implant
dose
reason
explant
occur
implant
group
includ
implant
wound
complic
n
eviscer
n
endophthalm
n
implant
protrus
n
uncontrol
glaucoma
n
scleral
necrosi
n
scleral
melt
n
retin
detach
n
tabl
present
proport
implant
eye
fellow
eye
iop
elev
mm
hg
time
postimplant
period
highest
proport
studi
eye
iop
elev
mm
hg
fa
implant
group
respect
seen
postimplant
visit
thereaft
proport
decreas
throughout
remain
month
followup
differ
implant
eye
fellow
eye
year
followup
signific
dose
p
howev
differ
dose
implant
eye
signific
p
case
hypotoni
defin
iop
mm
hg
observ
implant
group
implant
eye
experienc
hypotoni
sometim
followup
period
compar
fellow
nonimpl
eye
p
implant
group
hypotoni
occur
implant
eye
followup
period
compar
fellow
nonimpl
eye
p
differ
eye
treat
implant
signific
p
instanc
hypotoni
occur
shortli
implant
surgeri
ioplow
surgeri
rate
chang
len
opac
baselin
subcapsular
nuclear
cortic
len
region
evalu
use
loc
ii
scale
overal
increas
subcapsular
len
opac
observ
phakic
implant
eye
dose
group
combin
compar
phakic
nonimpl
fellow
eye
year
postimplant
p
len
opac
increas
nuclear
cortic
segment
observ
phakic
implant
eye
respect
dose
group
combin
year
postimplant
compar
respect
fellow
nonimpl
eye
postimplant
followup
period
phakic
implant
eye
dose
combin
cataract
surgeri
compar
phakic
nonimpl
fellow
eye
cataract
surgeri
implant
eye
occur
year
month
postimplant
visual
field
sensit
quantifi
mean
deficit
md
measur
decibel
db
year
postimplant
md
decreas
db
implant
group
improv
db
implant
group
p
statist
signific
withingroup
chang
md
studi
fellow
eye
dose
group
dose
group
combin
implant
group
implant
eye
reduct
md
time
postimplant
followup
period
compar
fellow
nonimpl
eye
p
implant
group
implant
eye
reduct
md
time
postimplant
followup
period
compar
fellow
nonimpl
eye
p
statist
signific
differ
treatment
nonocular
ae
report
patient
dose
group
combin
frequent
observ
nonocular
ae
headach
nasopharyng
arthralgia
pyrexia
cours
studi
three
patient
die
one
implant
group
abdomin
aortic
aneurysm
two
implant
group
sudden
cardiac
arrest
pneumonia
none
death
relat
studi
drug
result
studi
demonstr
fa
intravitr
implant
effect
treatment
nipu
predominantli
asian
patient
popul
fa
intravitr
implant
effect
reduc
rate
uveiti
recurr
improv
visual
outcom
compar
nonimpl
fellow
eye
degre
improv
rel
nonimpl
fellow
eye
especi
notabl
given
patient
bilater
nipu
sever
affect
eye
implant
uveiti
recurr
rate
eye
treat
fa
intravitr
implant
combin
dose
group
decreas
preimplant
period
postimplant
period
control
maintain
year
visual
acuiti
implant
eye
stabil
improv
eye
signific
number
eye
demonstr
line
improv
year
postimplant
furthermor
eye
treat
fa
intravitr
implant
reduc
need
adjunct
system
therapi
periocular
topic
corticosteroid
inject
control
uveiti
data
consist
two
previou
studi
evalu
fa
intravitr
implant
treatment
nipu
market
fa
intravitr
implant
retisert
fa
intravitr
implant
demonstr
similar
efficaci
although
higherdos
implant
tend
shorter
time
uveiti
recurr
attribut
shorter
lifespan
implant
consist
known
vitro
releas
rate
data
suggest
drug
reservoir
deplet
rapidli
higherdos
implant
main
caus
visual
loss
patient
posterior
uveiti
cme
abil
fa
implant
reduc
cme
control
inflamm
led
good
visual
acuiti
outcom
improv
visual
acuiti
outcom
observ
despit
format
cataract
major
implant
patient
cataract
format
progress
common
eye
uveiti
attribut
inflammatori
progress
chronic
use
corticosteroid
control
diseas
studi
nearli
implant
phakic
eye
underw
cataract
surgeri
followup
high
incid
reduct
bcva
line
observ
month
period
followup
cataract
surgeri
perform
implant
eye
howev
follow
cataract
remov
implant
eye
visual
acuiti
improv
signific
improv
mean
bcva
compar
baselin
implant
group
year
postimplant
implant
eye
dose
group
combin
improv
line
baselin
year
postimplant
significantli
greater
proport
observ
fellow
nonimpl
eye
p
notabl
followup
post
hoc
analysi
postsurg
outcom
eye
requir
cataract
extract
earlier
phase
iiiii
studi
fa
implant
treatment
nipu
sheppard
et
al
report
better
vision
less
intraocular
inflamm
follow
cataract
surgeri
implant
eye
compar
nonimpl
eye
result
remark
studi
well
current
studi
faimplant
eye
repres
patient
wors
eye
month
postcataract
extract
mean
improv
visual
acuiti
significantli
greater
implant
nonimpl
eye
p
significantli
fewer
ac
cell
seen
implant
nonimpl
eye
p
elev
iop
also
common
uveit
eye
due
occlus
aqueou
outflow
inflammatori
debri
andor
format
peripher
anterior
synechia
herbert
et
al
report
preval
elev
iop
uveiti
patient
high
case
requir
treatment
manag
elev
iop
proport
implant
eye
experienc
elev
iop
studi
higher
eye
implant
group
respect
due
fact
corticosteroid
treatment
may
also
lead
reduc
aqueou
outflow
varieti
mechan
major
implant
eye
iop
elev
success
treat
ioplow
medic
implant
eye
iop
elev
requir
glaucomafilt
procedur
control
iop
detail
topic
ioplow
medic
filter
procedur
util
studi
two
previou
fa
implant
studi
describ
goldstein
et
al
trabeculectomi
common
surgic
procedur
previou
studi
surgic
procedur
deem
success
eye
year
postop
iop
mm
hg
without
addit
ioplow
medic
might
expect
ocular
ae
implant
eye
compar
nonimpl
fellow
eye
advers
event
nonimpl
eye
appear
reflect
larg
part
underli
uveit
process
eg
reduc
visual
acuiti
cataract
eye
pain
increas
iop
conjunctiv
hyperemia
vitreou
floater
blur
vision
macular
edema
ae
implant
eye
consist
surgic
procedur
corticosteroid
deliv
eg
increas
iop
eye
pain
conjunctiv
hermorrhag
postop
wound
complic
cataract
format
notabl
nonocular
ae
consid
treatment
relat
either
implant
group
find
like
due
neglig
system
exposur
fa
follow
implant
fa
implant
previou
studi
patient
receiv
intravitr
implant
blood
sampl
taken
variou
time
implant
plasma
level
fa
limit
detect
dosecontrol
design
studi
along
lack
random
regard
treatment
eye
bilater
case
preclud
definit
distinct
regress
mean
explan
appar
treatment
effect
mani
clinic
find
includ
visual
acuiti
recurr
inflamm
biolog
plausibl
magnitud
result
howev
suggest
treatment
effect
primari
contributor
result
result
studi
demonstr
efficaci
fa
intravitr
implant
treatment
nipu
popul
predominantli
asian
patient
fa
intravitr
implant
led
signific
reduct
uveiti
recurr
rate
improv
visual
acuiti
elev
iop
cataract
format
common
ae
consist
natur
histori
diseas
treatment
use
unlik
previou
studi
complic
relat
implant
site
wound
leak
therefor
especi
import
physician
pay
care
attent
wound
closur
uveit
patient
treat
fa
implant
